Ryan L. Bjordahl, Ph.D.
Affiliations: | 2011 | University of Colorado Anschutz Medical Campus, Denver, Aurora, CO |
Area:
Cell Biology, Physiology BiologyGoogle:
"Ryan Bjordahl"Parents
Sign in to add mentor| Yosef Refaeli | grad student | 2011 | University of Colorado, Denver | |
| (The function of T cells in B cell lymphoma growth.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Dixon KJ, Snyder KM, Khaw M, et al. (2024) iPSC-derived NK cells expressing high-affinity IgG Fc receptor fusion CD64/16A to mediate flexible, multi-tumor antigen targeting for lymphoma. Frontiers in Immunology. 15: 1407567 |
| Snyder KM, Dixon KJ, Davis Z, et al. (2023) iPSC-derived natural killer cells expressing the FcγR fusion CD64/16A can be armed with antibodies for multitumor antigen targeting. Journal For Immunotherapy of Cancer. 11 |
| Goulding J, Yeh WI, Hancock B, et al. (2023) A chimeric antigen receptor uniquely recognizing MICA/B stress proteins provides an effective approach to target solid tumors. Med (New York, N.Y.) |
| Cichocki F, Bjordahl R, Goodridge JP, et al. (2022) Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma. Nature Communications. 13: 7341 |
| Cichocki F, Goodridge J, Bjordahl R, et al. (2022) Dual-antigen targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia. Blood |
| Woan KV, Kim H, Bjordahl R, et al. (2021) Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy. Cell Stem Cell |
| Chiu E, Felices M, Cichocki F, et al. (2021) Anti-NKG2C/IL-15/anti-CD33 Killer Engager Directs Primary and iPSC-derived NKG2C NK cells to Specifically Target Myeloid Leukemia. Molecular Therapy : the Journal of the American Society of Gene Therapy |
| Cichocki F, Bjordahl R, Gaidarova S, et al. (2020) iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti-PD-1 therapy. Science Translational Medicine. 12 |
| Zhu H, Blum R, Bjordahl R, et al. (2019) Pluripotent stem cell-derived NK cells with high-affinity non-cleavable CD16a mediate improved anti-tumor activity. Blood |
| Cichocki F, Valamehr B, Bjordahl R, et al. (2017) GSK 3 inhibition drives maturation of NK cells and enhances their antitumor activity. Cancer Research |